natgillin/translations-raw huggingface dataset:
‘Lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDLcholesterol (LDL-C), apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
„Zdravilo Lipitor je indicirano kot dopolnilo k prehrani za zniževanje povišanega celokupnega holesterola, holesterola LDL, apolipoproteina B in trigliceridov pri bolnikih s primarno hiperholesterolemijo, vključno z družinsko hiperholesterolemijo (heterozigotna različica) ali s kombinirano (mešano) hiperlipidemijo (ki ustreza tipoma IIa in IIb po Fredricksonovi klasifikaciji), kadar je odziv na dieto in druge nefarmakološke ukrepe nezadosten.
Lipitor is also indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.'
Zdravilo Lipitor je indicirano tudi za zniževanje celokupnega holesterola in holesterola LDL pri bolnikih s homozigotno družinsko hiperholesterolemijo kot dodatek drugim načinom terapevtskega zniževanja lipidov (npr. aferezi LDL) ali če taki načini niso na voljo.“
Company responses provided on: 29 March 2010, 17 June 2010 Opinion date:
29. marca 2010, 17. junija 2010
Lipitor was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila v humani medicini (CMD(h)) je ugotovila, da je za zdravilo Lipitor potrebno usklajevanje.
Date of first authorisation: 23 April 2007 Date of latest renewal: 13 April 2012
Datum prve odobritve: 23. april 2007 Datum zadnjega podaljšanja: 13. april 2012
It may harm them,
driska, navzea pogosti:
Your doctor will tell you exactly how many capsules to take.
Zdravnik vam bo natančno povedal, koliko kapsul morate jemati.
This medicine should be taken once a day.
To zdravilo je treba jemati enkrat na dan.
Advagraf is used in adults.
Zdravilo Advagraf se uporablja pri odraslih.
Wear appropriate protective clothing and use a sunscreen with a high sun protection factor.
Nosite primerna zaščitna oblačila in uporabljajte sredstva za sončenje z visokim zaščitnim faktorjem.
Advagraf reduces your body's defence mechanism (immune system), which will not be as good at fighting infections.
Zdravilo Advagraf omeji obrambni mehanizem vašega telesa (imunski sistem), ki ne bo tako dober pri premagovanju okužb.
pancreatic pseudocyst, subileus
psevdocista pankreasa, subileus
Advagraf with food and drink
Zdravilo Advagraf skupaj s hrano in pijačo
Take Advagraf on an empty stomach or 2 to 3 hours after a meal.
Zdravilo Advagraf vzemite na prazen želodec ali 2 do 3 ure po jedi.
This medicine should only be prescribed to you by a doctor with experience in the treatment of transplant patients.
To zdravilo vam lahko predpiše samo zdravnik z izkušnjami v zdravljenju bolnikov s presaditvami.
Do not take a double dose the next morning.
Naslednje jutro ne vzemite dvojnega odmerka.
Older peoples There is no evidence currently available to indicate that dosing should be adjusted in older people.
Starejši ljudje Trenutno ni dokazov, da bi bila pri starejših ljudeh potrebna prilagoditev odmerjanja.
Advagraf and Prograf are not interchangeable.
Zdravili Advagraf in Prograf nista zamenljivi.
Advagraf doses are usually reduced in the post-transplant period.
Odmerki zdravila Advagraf se med obdobjem po presaditvi ponavadi zmanjšajo.
No studies on the effects of tacrolimus (Advagraf) on the ability to drive and use machines have been performed.
Študij o vplivu takrolimusa (Advagraf) na sposobnost vožnje in upravljanja s stroji niso izvedli.
The frequency of adverse reactions is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni po pogostnosti takole: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
What Advagraf is and what it is used for
Kaj je zdravilo Advagraf in za kaj ga uporabljamo
If the appearance of this medicine is not the same as usual, or if dosage instructions have changed, speak to your doctor or pharmacist as soon as possible to make sure that you have the right medicine.
Če videz tega zdravila ni enak kot običajno ali so se spremenila navodila za jemanje, se čimprej pogovorite z zdravnikom ali s farmacevtom, da zagotovite, da imate pravo zdravilo.
If you have forgotten to take your Advagraf capsules in the morning, take them as soon as possible on the same day.
Če ste zjutraj Advagraf kapsule pozabili vzeti, jih vzemite isti dan takoj, ko je to možno.
Administration should commence approximately 12-18 hours after the completion of surgery.
Začeti se mora približno 12-18 ur po koncu operacije.
Tacrolimus is not compatible with PVC (polyvinylchloride).
Takrolimus ni kompatibilen s polivinilkloridom (PVC).
It is an immunosuppressant.
Je imunosupresiv.
A number of associated cases of transplant rejection have been reported (frequency cannot be estimated from available data).
Ob tem so poročali o nekaj primerih s tem povezanih zavrnitev presadka (iz razpoložljivih podatkov pogostnosti ni mogoče oceniti).
Other medicines and Advagraf
Druga zdravila in zdravilo Advagraf
After opening the aluminium wrapper: 1 year
Po odprtju aluminijastega ovoja: 1 leto.
You will need to take Advagraf every day as long as you need immunosuppression to prevent rejection of your transplanted organ.
Zdravilo Advagraf boste morali jemati vsak dan, dokler potrebujete imunosupresijo za preprečitev zavrnitve presajenega organa.
Do not use Advagraf after the expiry date which is stated on the carton after “Exp”.
Zdravila Advagraf ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake ''Exp''.
Severe effects may occur, including allergic and anaphylactic reactions.
Pojavijo se lahko resni neželeni učinki, vključno z alergijskimi in anafilaktičnimi reakcijami.
Not known (frequency cannot be estimated from the available data): - Abnormality of the optic nerve (optic neuropathy)
Ni znano (pogostnosti ni mogoče oceniti na podlagi podatkov, ki so na voljo): - prizadetost vidnega živca (nevropatija vidnega živca)
Certain combinations of tacrolimus with drugs known to have nephrotoxic or neurotoxic effects may increase the risk of these effects (see section 4.5).
Določene kombinacije takrolimusa z zdravili, za katere je znano, da imajo nefrotoksične ali nevrotoksične učinke, lahko povečajo tveganje za te učinke (glejte poglavje 4.5).
An updated RMP should be submitted: - At the request of the European Medicines Agency, - Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Posodobljen RMP je treba predložiti: - na zahtevo Evropske agencije za zdravila; - ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
Stopping your treatment with Advagraf may increase the risk of rejection of your transplanted organ.
Prekinitev zdravljenja z zdravilom Advagraf lahko poveča tveganje za zavrnitev presajenega organa.
If you are allergic to peanut or soya, talk to your doctor to determine whether you should use this medicine.
Če ste alergični na arašide ali sojo, se posvetujte s svojim zdravnikom, da presodi ali lahko uporabljate to zdravilo.
Tubing, syringes and other equipment used to prepare a suspension of Advagraf capsule contents must not contain PVC.
Cevke, brizge in drugi pripomočki, ki se jih uporablja za pripravo suspenzije iz zdravila Advagraf kapsule, ne smejo vsebovati PVC-ja.
As detrimental effects on the newborn cannot be excluded, women should not breast-feed whilst receiving Advagraf.
Ker ni mogoče izključiti škodljivih učinkov na novorojenčka, ženske med uporabo zdravila Advagraf ne smejo dojiti.
The MAH shall perform the pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
The safety and efficacy of Advagraf in children under 18 years of age have not yet been established.
Varnost in učinkovitost zdravila Advagraf pri otrocih, mlajših od 18 let, še nista bili dokazani.
A double dose should not be taken on the next morning.
Naslednje jutro ne sme vzeti dvojnega odmerka.
The incidences of acute rejection were numerically lower with tacrolimus in all three studies and one of the studies reported a significantly lower incidence of bronchiolitis obliterans syndrome with tacrolimus.
Incidenca akutnih zavrnitev je bila v vseh treh študijah številčno manjša s takrolimusom in v eni od teh študij so poročali o značilno manjši incidenci obliteracijskega bronhiolitisa pri uporabi takrolimusa.
Like all medicines, Advagraf can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Advagraf neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Therefore, in this patient group, EBV-VCA serology should be ascertained before starting treatment with Advagraf.
Pri tej skupini bolnikov je pred začetkom zdravljenja z zdravilom Advagraf treba izvesti serološko testiranje na EBV-VCA.
If you are, think you might be or are planning to become pregnant, ask your doctor for advice before using Advagraf.
Če ste noseči, mislite, da ste noseči ali nameravate zanositi, se posvetujte z zdravnikom, preden uporabite zdravilo Advagraf.
The printing ink used to mark the capsule contains trace amounts of soya lecithin (0.48% of total printing ink composition).
Tiskarsko črnilo, ki se uporablja za označevanje kapsul, vsebuje v sledovih sojin lecitin (0,48 % celotne sestave tiskarskega črnila).
If signs of toxicity such as severe adverse reactions are noted (see section 4.8), the dose of Advagraf may need to be reduced.
Če se pojavijo znaki toksičnosti, na primer resni neželeni učinki (glejte poglavje 4.8), bo odmerek zdravila Advagraf morda treba zmanjšati.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
From time to time, your doctor may need to do blood, urine, heart, eye tests, to set the right dose of Advagraf.
Zdravnik vam bo od časa do časa moral narediti preiskave krvi, urina, srca in vida, da bo določil pravi odmerek zdravila Advagraf.
Data from clinical studies suggest that the majority of patients can be successfully managed if tacrolimus blood trough levels are maintained below 20 ng/ml.
Podatki iz kliničnih študij kažejo, da je mogoče večino bolnikov uspešno nadzirati, če je najnižja koncentracija takrolimusa v krvi vzdrževana pod 20 ng/ml.
Hypersensitivity to tacrolimus, or to any of the excipients listed in section 6.1 Hypersensitivity to other macrolides
Preobčutljivost na takrolimus ali katerokoli pomožno snov, navedeno v poglavju 6.1 Preobčutljivost na druge makrolide
Accordingly, high-risk patients receiving substantial immunosuppression should be monitored, using such procedures as echocardiography or ECG pre- and post-transplant (e.g. initially at 3 months and then at 9 -12 months).
Glede na to je treba zelo ogrožene bolnike, ki se zdravijo z intenzivno imunosupresijo, nadzorovati s preiskavami, kot sta ehokardiografija ali EKG, in sicer pred presaditvijo in po njej (npr. uvodoma po 3 mesecih in potem pri 9-12 mesecih).
In case of in utero exposure, monitoring of the newborn for the potential adverse events of tacrolimus is recommended (in particular effects on the kidneys).
V primeru izpostavljenosti in utero je novorojenčka priporočljivo nadzirati glede možnih neželenih učinkov takrolimusa (zlasti učinki na ledvice).
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
The use of Advagraf is not recommended in children and adolescents under 18 years.
Otroci in mladostniki Uporaba zdravila Advagraf ni priporočljiva pri otrocih in mladostnikih, mlajših od 18 let.
Overall, the safety profile of oral Prograf in these published studies appeared to be similar to what was reported in the large studies, where Prograf was used as primary treatment in liver, kidney and heart transplantation.
V celoti so bile varnostne značilnosti zdravila Prograf v peroralni obliki v teh objavljenih študijah podobne tistemu, kar je znano iz velikih študij, v katerih so zdravilo Prograf v peroralni obliki uporabljali kot primarno zdravljenje po presaditvi jeter, ledvic in srca.
There is a risk for premature delivery (<37 week) (incidence of 66 of 123 births, i.e. 53.7%; however, data showed that the majority of the newborns had normal birth weight for their gestational age) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e. 7.2 %) which, however normalises spontaneously.
Obstaja tveganje za prezgoden porod (< 37 tednov) (pri 66 od 123 rojstev, tj. pojavnost 53,7 %; vendar podatki kažejo, da je imela večina novorojenčkov normalno telesno maso za njihovo gestacijsko starost) in za hiperkaliemijo pri novorojenčku (pri 8 od 111 novorojenčkov; pojavnost 7,2 %), ki pa se normalizira sama od sebe.
Patients treated with tacrolimus have been reported to develop Epstein-Barr-Virus (EBV)-associated lymphoproliferative disorders (see section 4.8).
Pri bolnikih, ki so se zdravili s takrolimusom, so poročali o pojavu z Epstein-Barr virusom (EBV) povezanih limfoproliferativnih bolezni (glejte poglavje 4.8).
Advagraf passes into breast milk.
Zdravilo Advagraf prehaja v materino mleko.
Significantly more ciclosporintreated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995;60:580).
S ciklosporina na takrolimus je moralo preiti statistično značilno več bolnikov (n = 13) kot s takrolimusa na ciklosporin (n = 2) (p = 0,02) (Keenan et al., Ann Thoracic Surg 1995;60:580).
Bile flow does not influence the absorption of tacrolimus and therefore treatment with Advagraf may commence orally.
Tok žolča ne vpliva na absorpcijo takrolimusa, zato se zdravljenje z zdravilom Advagraf lahko začne peroralno.
Tacrolimus blood trough levels should be determined approximately 24 hours post-dosing of Advagraf, just prior to the next dose.
Najnižjo koncentracijo takrolimusa je treba določiti približno 24 ur po uporabi zdravila Advagraf, tik pred naslednjim odmerkom.
Published clinical experience from a single centre on the use of oral Prograf for primary treatment following intestinal transplantation showed that the actuarial survival rate of 155 patients (65 intestine alone, 75 liver and intestine, and 25 multivisceral) receiving tacrolimus and prednisone was 75% at 1 year, 54% at 5 years, and 42% at 10 years.
Objavljene klinične izkušnje enega samega centra o uporabi peroralne oblike zdravila Prograf pri primarnem zdravljenju po presaditvi črevesa kažejo, da je bilo aktuarsko preživetje 155 bolnikov (65 samo črevo, 75 jetra in črevo, 25 multivisceralno), ki so dobivali takrolimus in prednizon, po 1 letu 75 %, po 5 letih 54 % in po 10 letih 42 %.
Also contains lactose and traces of soya lecithin.
Vsebuje tudi laktozo in sojin lecitin v sledovih.
Animal data have shown that tacrolimus could potentially decrease the clearance and increase the half-life of pentobarbital and antipyrine.
Podatki, zbrani na živalih, kažejo, da bi takrolimus lahko zmanjšal očistek in podaljšal razpolovni čas pentobarbitala in antipirina.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal preparations.
Obvestite zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta (vključno s pripravki rastlinskega izvora).
Limited data are available but no recommendation on a posology can be made.
Na voljo je malo podatkov, zato ni priporočil o odmerjanju.
What Advagraf is and what it is used for What you need to know before you take Advagraf How to take Advagraf
Kaj je zdravilo Advagraf in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Advagraf Kako jemati zdravilo Advagraf Možni neželeni učinki
Advagraf is used to control your body's immune response, enabling your body to accept the transplanted organ.
Zdravilo Advagraf uporabljamo za obvladovanje telesnega imunskega odziva, kar omogoči, da telo sprejme presajeni organ.
Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies, have been observed in Prograf treated patients on rare occasions and may also occur with Advagraf.
Ventrikularno hipertrofijo ali hipertrofijo septuma, opisani kot kardiomiopatije, so opazili v redkih primerih zdravljenja bolnikov z zdravilom Prograf in to se zgodi tudi pri uporabi zdravila Advagraf.
Peak blood concentrations achieved with these doses were above 150 ng/mL which is more than 6-fold higher than mean peak concentrations observed with Advagraf in clinical transplantation.
Najvišje koncentracije v krvi, dosežene s temi odmerki, so bile višje od 150 ng/ml, kar je več kot 6-krat višja vrednost od povprečne najvišje koncentracije, ki je bila opažena pri uporabi zdravila Advagraf pri presaditvah v klinični praksi.
If you stop taking Advagraf
Če ste prenehali jemati zdravilo Advagraf
If you forget to take Advagraf
Če ste pozabili vzeti zdravilo Advagraf
Advagraf therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient.
Zdravljenje z zdravilom Advagraf je treba začeti upoštevaje koncentracijo ciklosporina v krvi in bolnikovo klinično stanje.
Use all the capsules within 1 year of opening the aluminium wrapping and before the expiry date.
Vse kapsule morate porabiti v 1 letu po odprtju aluminijastega ovoja in pred datumom izteka roka uporabnosti zdravila.
Avoid grapefruit (also as juice) while on treatment with Advagraf, since it can affect its levels in the blood.
Med jemanjem zdravila Advagraf se morate izogibati uživanju grenivk (tudi v obliki soka), ker lahko vplivajo na njegove vrednosti v krvi.
Following your organ transplant (liver, kidney), your body's immune system will try to reject the new organ.
Po presaditvi organa (jeter, ledvic) telo poskuša zavrniti novi organ.
Neoplasms benign, malignant and unspecified Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
Benigne, maligne in neopredeljene novotvorbe Bolnike, ki prejemajo imunosupresive, bolj ogroža pojav malignomov.
Results from clinical trials performed with once-daily tacrolimus Advagraf Liver transplantation
Rezultati iz kliničnih preskušanj, izvedenih z odmerjanjem takrolimusa (Advagraf) enkrat dnevno Presaditev jeter
In patients unable to take oral medicinal products during the immediate post-transplant period, tacrolimus therapy can be initiated intravenously (see Summary of Product Characteristics for Prograf 5 mg/ml concentrate for solution for infusion) at a dose approximately 1/5th of the recommended oral dose for the corresponding indication.
Pri bolnikih, pri katerih jemanje peroralnih oblik zdravila takoj po presaditvi ni možno, se zdravljenje s takrolimusom lahko uvede intravensko (glejte povzetek glavnih značilnosti zdravila Prograf 5 mg/ml koncentrat za raztopino za infundiranje) v odmerku, ki je približno 1/5 priporočenega peroralnega odmerka za ustrezno indikacijo.
Use all the prolonged-release hard capsules within 1 year of opening the aluminium wrapping.
Vse trde kapsule s podaljšanim sproščanjem morate porabiti v 1 letu po odprtju aluminijastega ovoja.
It is not recommended that Advagraf is taken with ciclosporin (another medicine used for the prevention of transplant organ rejection).
Jemanje zdravila Advagraf skupaj s ciklosporinom (drugo zdravilo, ki se uporablja za preprečevanje zavrnitve organa po presaditvi) ni priporočljivo.
At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound.
Kaže, da učinke takrolimusa na molekulski ravni sproži vezava na citosolno beljakovino (FKBP12), ki je odgovorna za njegovo znotrajcelično kopičenje.
You may also be given Advagraf for an ongoing rejection of your transplanted liver, kidney, heart or other organ when any previous treatment you were taking was unable to control this immune response after your transplantation.
Zdravilo Advagraf lahko dobite tudi zaradi zavračanja presajenih jeter, ledvic, srca ali drugega organa, oziroma če zdravila, ki ste jih jemali pred tem, niso obvladala imunskega odziva po presaditvi.
If abnormalities develop, dose reduction of Advagraf, or change of treatment to another immunosuppressive agent should be considered.
Če se pojavijo nenormalnosti, je treba razmisliti o zmanjšanju odmerka zdravila Advagraf ali o prehodu na drugo imunosupresivno zdravilo.
Other potential interactions that may increase systemic exposure of tacrolimus include prokinetic agents (such as metoclopramide and cisapride), cimetidine and magnesium-aluminium-hydroxide.
Druge možne interakcije, ki lahko povečajo sistemsko izpostavljenost takrolimusa vključujejo interakcije s propulzivi (kot sta metoklopramid in cisaprid), cimetidinom in magnezijevim/aluminijevim hidroksidom.
Make sure that you receive the same tacrolimus medicine every time you collect your prescription, unless your transplant specialist has agreed to change to a different tacrolimus medicine.
Ko greste z receptom v lekarno, se vedno prepričajte, da ste dobili enako zdravilo s takrolimusom, razen če se je zdravnik, strokovnjak za presaditve, strinjal z zamenjavo z drugim zdravilom s takrolimusom.
Advagraf should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption (see section 5.2).
Za dosego največje absorpcije je treba zdravilo Advagraf praviloma jemati na prazen želodec ali vsaj 1 uro pred ali 2 do 3 ure po jedi (glejte poglavje 5.2).
If you have accidentally taken too much Advagraf, contact your doctor or nearest hospital emergency department immediately.
Če ste vzeli večji odmerek zdravila Advagraf, kot bi smeli Če ste po nesreči vzeli preveč zdravila Advagraf, se takoj obrnite na svojega zdravnika ali oddelek za nujno pomoč v najbližji bolnišnici.
Advagraf blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking Advagraf, which may require interruption, an increase or a decrease in Advagraf dose.
Druga zdravila, ki jih jemljete, lahko vplivajo na koncentracijo zdravila Advagraf v krvi, pa tudi jemanje zdravila Advagraf lahko vpliva na koncentracijo drugih zdravil v krvi, zato utegne biti potrebna prekinitev, povečanje ali zmanjšanje odmerka zdravila Advagraf.